Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075113 Target Snapshot

Toll-like receptor 3 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
289Compounds
50Assays
0Approved Drugs
36.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Toll-like receptor 3 shows late clinical disease relevance led by age-related macular degeneration. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O15455. Start with age-related macular degeneration, then reuse UniProt O15455 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with age-related macular degeneration, then reuse UniProt O15455 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
age-related macular degeneration

Toll-like receptor 3 shows late clinical disease relevance led by age-related macular degeneration. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with age-related macular degeneration because it currently carries late clinical support. Linked drugs include BEVASIRANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Toll-like receptor 3 as ChEMBL target CHEMBL1075113, mapped to UniProt O15455. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Toll-like receptor 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1075113
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O15455
Toll-like receptor 3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Toll-like receptor 3 is the right protein anchor across sources, using UniProt O15455 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why age-related macular degeneration is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameToll-like receptor 3
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO15455
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelToll-like receptor 3
UniProt AccessionO15455
Component TypeProtein
Sequence Length904 aa

Toll-like receptor 3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Toll-like receptor 3, mapped to UniProt O15455. Sequence length is 904 aa.

Mapped IDO15455
Review nameToll-like receptor 3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Toll-like receptor 3 shows late clinical disease relevance led by age-related macular degeneration. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
age-related macular degeneration
1 linked drug · 1 direct · 1 efficacy
Linked drugBEVASIRANIB
Late clinical Phase III
chronic fatigue syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugRINTATOLIMOD
Late clinical Phase III
encephalomyelitis
1 linked drug · 1 direct · 1 efficacy
Linked drugRINTATOLIMOD
Late clinical Phase III
macular degeneration
1 linked drug · 1 direct · 1 efficacy
Linked drugBEVASIRANIB
Clinical signal Phase II
long COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugRINTATOLIMOD
Clinical signal Phase II
melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugRINTATOLIMOD
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with age-related macular degeneration because it currently carries late clinical support. Linked drugs include BEVASIRANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseage-related macular degeneration
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC507.0
KI1.0
EC5028.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL19954 6.96 IC50 110.0 Preclinical
CHEMBL4647818 5.67 IC50 2160.0 Preclinical
CHEMBL4795714 5.62 IC50 2400.0 Preclinical
CHEMBL4303728 5.53 Ki 2960.0 Preclinical
CHEMBL4303728 5.46 IC50 3440.0 Preclinical
CHEMBL4074408 5.32 EC50 4800.0 Preclinical
CHEMBL4636498 5.26 IC50 5440.0 Preclinical
CHEMBL4105063 4.65 EC50 22300.0 Preclinical
CHEMBL4064228 4.37 EC50 42500.0 Preclinical
Distribution

pChEMBL Value Distribution

4
5.0
3
5.5
0
6.0
1
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

50
Total Assays
11
Tested Compounds
2
Assay Types
Binding — 47 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 40 7 5.4
single protein format 4 4 5.2
assay format 3 0 —
Functional — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 3 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine